In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Effect of aortic valve calcification as measured by computed tomography in patients undergoing transcatheter aortic valve implantation.

Session Aortic valve imaging pre and post intervention

Speaker Konstantinos Toutouzas

Congress : ESC Congress 2018

  • Topic : imaging
  • Sub-topic : Imaging: Diseases of the Aorta
  • Session type : Advances in Science
  • FP Number : 5250

Authors : K Stathogiannis (Athens,GR), K Toutouzas (Athens,GR), M Drakopoulou (Athens,GR), G Latsios (Athens,GR), A Synetos (Athens,GR), G Oikonomou (Athens,GR), M Xanthopoulou (Athens,GR), G Trantalis (Athens,GR), A Papanikolaou (Athens,GR), G Peskesis (Athens,GR), E Tsiamis (Athens,GR), D Tousoulis (Athens,GR)

Authors:
K. Stathogiannis1 , K. Toutouzas1 , M. Drakopoulou1 , G. Latsios1 , A. Synetos1 , G. Oikonomou1 , M. Xanthopoulou1 , G. Trantalis1 , A. Papanikolaou1 , G. Peskesis1 , E. Tsiamis1 , D. Tousoulis1 , 1Hippokration Hospital, University of Athens, 1st Department of Cardiology - Athens - Greece ,

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 1081

Background: Transcatheter aortic valve implantation (TAVI) is the mainstay for treating patients with severe aortic valve stenosis. The impact of calcium deposition in patients undergoing TAVI is not thoroughly investigated.

Purpose: We investigated the effect of aortic valve calcification in the clinical outcomes of patients undergoing TAVI with a self-expanding valve.

Methods: TAVI with a self-expanding bioprosthesis was performed in 175 high-risk patients with symptomatic severe aortic stenosis (age: 81±7 years; logistic EuroSCORE 22±8%; 56% females; NYHA III 90%). Patients with severe pre TAVI aortic regurgitation and bicuspid aortic valve disease were excluded. All patients underwent multislice computed tomography and all of them had calcium evaluation in a semi-quantitative way. The patients were then categorized into 3 groups according to the aortic valve's calcium deposition; group 1 had mild calcium, group 2 had moderate calcium deposition and group 3 had severe calcium deposition. All endpoints were considered as per the VARC-2 criteria.

Results: The total cohort was comprised of 175 patients, group 1 had 69 patients (39%), group 2 had 64 patients (37%) and group 3 had 42 (24%). Device success was similar among the groups (88% in group 1 vs 85% in group 2 vs 81% in group 3, p=0.15) and so was fluoroscopy time (23min in group 1 vs 25 min in group 2 vs 25 in group 3, p=0.54). Group 3 had higher rates of paravalvular leakage (PVL) after TAVI compared to the other groups. More specifically, patients in group 3 had higher rates of moderate/severe PVL (33% vs 19% in group 2 vs 8% in group 1, p=0.027 for all calculations). Patients in group 3 had higher new pacemaker implantation rates post TAVI compared to the other groups (40% vs 37% in group 2 vs 20% in group 1, p=0.032). Patients in group 3 had higher, although non-statistical significant stroke rates (4.8% vs 1.6% in group 2 vs 0% in group 1, p=0.141). Two-year mortality was similar among the groups (12% in group 1 vs 5.5% in group 2 vs 9.5% in group 3, p=0.39). In multivariate analysis, severe calcium deposition was proved to be an independent predictor of moderate/severe PVL post TAVI (p=0.002, OR 5.8, 95% CI 1.9–17.7).

Conclusion: Increased deposition of calcium in the aortic valve confers an adverse effect in patients undergoing TAVI with a self-expanding valve without effect in long-term mortality.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are